Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H M Jansen

Showing results (201-210 of 251) with videos related to

Pageof 26
Sort By:
Breast Cancer Research and Treatment|May 24, 2023
Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancerM K Bos, S W Lam, G Motta, et al.
Metabolism: Clinical and Experimental|July 6, 2012
Low-grade inflammation and insulin resistance independently explain substantial parts of the association between body fat and serum C3: the CODAM studyNick Wlazlo, Marleen M J van Greevenbroek, Isabel Ferreira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective studyMaurice P H M Jansen, Anieta M Sieuwerts, Maxime P Look, et al.
Annals of Translational Medicine|September 17, 2021
Liquid biopsy in esophageal cancer: a case report of false-positive circulating tumor DNA detection due to clonal hematopoiesisJonathan Spoor, Ben M Eyck, Peggy N Atmodimedjo, et al.
Molecular Oncology|February 7, 2017
Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditionsLisanne F van Dessel, Nick Beije, Jean C A Helmijr, et al.
Breast Cancer Research and Treatment|February 27, 2008
TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancerDanielle Meijer, Maurice P H M Jansen, Maxime P Look, et al.
BMC Cancer|February 13, 2022
The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancerSilvia R Vitale, Kirsten Ruigrok-Ritstier, A Mieke Timmermans, et al.
Breast Cancer Research and Treatment|March 23, 2010
Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancerE A Reijm, M P H M Jansen, K Ruigrok-Ritstier, et al.
Molecular Oncology|December 6, 2018
High-throughput isolation of circulating tumor DNA: a comparison of automated platformsLisanne F van Dessel, Silvia R Vitale, Jean C A Helmijr, et al.
The British Journal of Surgery|April 12, 2026
Presurgical levels of circulating tumour DNA in patients with resectable chemotherapy-naïve colorectal liver metastases: association with multiorgan recurrence and survival in the MIRACLE cohortLissa Wullaert, Lotte van Leeuwen, Vanja de Weerd, et al.
Pageof 26

Showing results (201-210 of 251) with videos related to

Sort By:
Pageof 26
Breast Cancer Research and Treatment|May 24, 2023
Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancerM K Bos, S W Lam, G Motta, et al.
Metabolism: Clinical and Experimental|July 6, 2012
Low-grade inflammation and insulin resistance independently explain substantial parts of the association between body fat and serum C3: the CODAM studyNick Wlazlo, Marleen M J van Greevenbroek, Isabel Ferreira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective studyMaurice P H M Jansen, Anieta M Sieuwerts, Maxime P Look, et al.
Annals of Translational Medicine|September 17, 2021
Liquid biopsy in esophageal cancer: a case report of false-positive circulating tumor DNA detection due to clonal hematopoiesisJonathan Spoor, Ben M Eyck, Peggy N Atmodimedjo, et al.
Molecular Oncology|February 7, 2017
Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditionsLisanne F van Dessel, Nick Beije, Jean C A Helmijr, et al.
Breast Cancer Research and Treatment|February 27, 2008
TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancerDanielle Meijer, Maurice P H M Jansen, Maxime P Look, et al.
BMC Cancer|February 13, 2022
The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancerSilvia R Vitale, Kirsten Ruigrok-Ritstier, A Mieke Timmermans, et al.
Breast Cancer Research and Treatment|March 23, 2010
Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancerE A Reijm, M P H M Jansen, K Ruigrok-Ritstier, et al.
Molecular Oncology|December 6, 2018
High-throughput isolation of circulating tumor DNA: a comparison of automated platformsLisanne F van Dessel, Silvia R Vitale, Jean C A Helmijr, et al.
The British Journal of Surgery|April 12, 2026
Presurgical levels of circulating tumour DNA in patients with resectable chemotherapy-naïve colorectal liver metastases: association with multiorgan recurrence and survival in the MIRACLE cohortLissa Wullaert, Lotte van Leeuwen, Vanja de Weerd, et al.
Pageof 26